{
  "title": "Paper_994",
  "abstract": "pmc Pharmaceuticals (Basel) Pharmaceuticals (Basel) 2102 pharmaceuticals pharmaceuticals Pharmaceuticals 1424-8247 Multidisciplinary Digital Publishing Institute  (MDPI) PMC12472772 PMC12472772.1 12472772 12472772 41011294 10.3390/ph18091355 pharmaceuticals-18-01355 1 Correction Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 16 Hou Zhenyan 1 Lin Songwen 1 2 Du Tingting 1 Wang Mingjin 1 Wang Weida 1 You Shen 1 Xue Nina 1 Liu Yichen 1 Ji Ming 1 2 * Xu Heng 1 * Chen Xiaoguang 1 3 * 1 houzhenyan@imm.ac.cn linsongwen@imm.ac.cn ninadu@imm.ac.cn wangmingjin@imm.ac.cn wangweida@imm.ac.cn youshen@imm.ac.cn angelnina@imm.ac.cn liuyichen@joinn-lab.com 2 3 * jiming@imm.ac.cn xuheng@imm.ac.cn chxg@imm.ac.cn 10 9 2025 9 2025 18 9 497460 1355 10 7 2025 02 9 2025 10 09 2025 27 09 2025 29 09 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer 16 5 15 5 2023 749 Pharmaceuticals 10.3390/ph16050749 PMC10221130 37242532 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes Error in Funding In the original publication [ 1 Funding: Error in Figure In the original publication [ 1  Disclaimer/Publisher’s Note: Reference 1. Hou Z. Lin S. Du T. Wang M. Wang W. You S. Xue N. Liu Y. Ji M. Xu H. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer Pharmaceuticals 2023 16 749 10.3390/ph16050749 37242532 PMC10221130 ",
  "metadata": {
    "Title of this paper": "S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer",
    "Journal it was published in:": "Pharmaceuticals",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472772/"
  }
}